Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: Focus on felodipine William C. LittleChe-Ping ChengMargareta Nordlander Review Pages: 657 - 663
Blockade of the human platelet GPIIb/IIIa receptor by a murine monoclonal antibody Fab fragment (7E3): Potent dose-dependent inhibition of platelet function Shoumo BhattacharyaRobert JordanAvijit Lahiri Platelet Function Pages: 665 - 675
Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs Adrian S. DobsMukesh PrasadDonald R. Hoover Lipid-Lowering Drugs Pages: 677 - 684
Pharmacodynamics and pharmacokinetics of clentiazem and diltiazem in closed-chest anesthetized dogs Sylvie GiassonDenis GarceauLouis Dumont Calcium Antagonists Pages: 685 - 692
Angiotensin II receptor antagonists in heart failure: Rationale and design of the evaluation of losartan in the elderly (ELITE) trial Bertram PittPaul ChangPieter B. M. WW. M. Timmermans Heart Failure Pages: 693 - 700
Experimental rat model representing both acute and chronic heart failure related to autoimmune myocarditis Sen KoyamaMakoto KodamaAkira Shibata Heart Failure Pages: 701 - 707
Electrophysiological evaluation of the sodium-channel blocker carbamazepine in healthy human subjects Göran KennebäckLennart BergfeldtTorbjörn Tomson Antiarrhythmics Pages: 709 - 714
Rate-dependent anisotropic conduction property in the epicardial border zone of canine myocardial infarcts and its modification by moricizine Noriyuki TsutsumiHideo MitamuraSatoshi Ogawa Antiarrhythmics Pages: 715 - 722
Digoxin and increased mortality among patients recovering from acute myocardial infarction: Importance of digoxin dose Jonathan LeorUri Goldbourtthe SPRINT Study Group Digoxin Pages: 723 - 729